This site uses cookies to provide a better browsing experience. More information can be found on our Privacy Policy page.

Hear from clinical experts on peripheral artery disease, inflammation science and the evolving role of NLRP3 inhibition. Explore Leadership Perspectives

publications & posters

Check out our scientific presentations to learn more about our ongoing drug development programs.

Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl] [(1-methyl-1H-pyrazol-4-yl)({[(2S)-oxolan-2-yl]methyl})sulfamoyl]azanide in Cellular and Mouse Models of Inflammation Provides a Translational Framework

Doedens, et al., ACS Pharmacology & Translational Science

Reversal of high fat diet-induced obesity, systemic inflammation and astrogliosis by the NLRP3 inflammasome inhibitors NT-0249 and NT-0796

Thornton, et al., The Journal of Pharmacology and Experimental Therapeutics

Target Cell Activation of a Structurally Novel NLRP3 Inhibitor NT-0796 Enhances Potency

Smolak, et al., Drug Discovery and Translational Medicine

Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders

Harrison, et al., Journal of Medicinal Chemistry

Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome Inhibitors

Harrison, et al., ACS Medicinal Chemistry Letters

Discovery of a series of ester-substituted NLRP3 inflammasome inhibitors

Harrison, et al., Bioorganic & Medicinal Chemistry Letters

See Our Development Pipeline